Racura Oncology Ltd · ASX:RAC
Racura Oncology — Investor Presentation (May 2021)
23 slides from Racura Oncology's investor presentation, May 5, 2021
Slide 1: ASX Announcement: Race investor briefing and updated presentation
ASX Announcement Race investor briefing and updated presentation § Updated investor presentation available which covers recent progress and coming milestones § Investor briefing to be held online on 13 May at 10:30am AEST 5 May 2021 – Race Oncology Limited (ASX: RAC) (Race) is pleased to release an
Slide 2: About Race Oncology (ASX: RAC)
About Race Oncology (ASX: RAC) Race Oncology is an ASX listed precision oncology company with a Phase II/III cancer drug called Bisantrene. Bisantrene is a potent inhibitor of the Fat mass and obesity associated (FTO) protein. Over-expression of FTO has been shown to be the genetic driver of a diver
Slide 3: Investor Update 30 April 2021
Investor Update 30 April 2021
Slide 4: Race Oncology Precision Oncology
@ , RACE ud ONCOLOGY PRECISION ONCOLOGY 4 RACE \@ ONcOLosy
Slide 5: Corporate snapshot
corporate snapshot ISSUED CAPITAL Shares 141.1m Options 20.9m Shareholders (30 April 2021) 9133 MARKET CAPITALISATION Share price (30 April 2021) $3.07 Market value (30 April 2021) $433m Cash (31 March 2021) $6.47m Enterprise value $426.5m SIGNIFICANT SHAREHOLDERS Daniel Tillett (Director & CSO) 9.6
Slide 6: 2020-2021 A pivotal period for bisantrene
2020-2021 A pivotal period for bisantrene May 2020 June 2020 Sept 2020 Nov 2020 Nov 2020 March 2021 April 2021 Race starts Bisantrene high- CCSA appointed Bisantrene data Breast cancer Multiple pre-clinical Appointment of preclinical breast lighted as potent clinical + FDA published in the clinical
Slide 7: Three heroes: The drug, The team, The three pillars strategy
Three heroes 1 The drug 2 The team 3 The three pillars strategy 5
Slide 8: 1. The drug. Bisantrene
1. The drug. bisantrene Bisantrene is an anti-cancer agent developed in the 1980s by Lederle Laboratories It was tested in >40 human trials; showed excellent activity in leukemia, breast and ovarian cancer and was approved in France for Acute Myeloid Leukemia (AML) Since acquiring Bisantrene, Race h
Slide 9: 2. The team: Seasoned board and executive, key opinion leaders
2. The team Seasoned board and executive, key opinion leaders BOARD Dr John Cullity, Mr Phil Lynch, Dr Daniel Tillett, Mary Harney Non-Executive Chairman CEO and Managing Director CSO and Executive Director Non-Executive Director MANAGEMENT Dr David Fuller Mr Phil Lynch, Dr Daniel Tillett, PhD Dr Ma
Slide 10: 2. The team. Extended Race team
2. The team. extended race team Business Advisors & Consultants Clinical Advisors Industry Partners and Scientific Collaborators Accountants Onyx Corporate Pty Ltd Clinical Advisory Prof. Borje Andersson, MD, PhD, MD Clinical Manufacturing Drug IrySys LLC Board Andersson Cancer Centre, USA Product C
Slide 11: 3. The three pillar strategy
3. the three pillar strategy Plan and progress clinical programs which prove efficacy and utility in targeted indications for GOAL Bisantrene, so that its potential is realised through sale to a scaled pharma Pillar 1 Pillar 2 Pillar 3 FTO Breast Cancer AML STRATEGIES Extramedullary Melanoma Move to
Slide 12: FTO: Central role in cancer
FTO Central ROLE In Cancer ● Scientific discoveries over the last decade have identified dysregulation (loss of control) of RNA methylation as a key driver of cancer development1 ● Changes in m6A RNA methylation control the expression of key genes in cancer development and growth2 ● Fatso/ Fat mass-
Slide 13: FTO Inhibitor Comparative Overview
FTO Inhibitor Comparative Overview IC50 Drug Potency1 Clinical Data Indications Efficacy & Known Side Effects References (nM) AML, Breast, doi.org/10.1016/j.ccell.2020.04.017 Leukopenia and myelosuppression at high doi.org/10.1016/j.molcel.2020.12.026 Bisantrene (CS1) 142.6 1 Yes (Phase 3) Pancreati
Slide 14: FTO inhibitors: Drug synergies
FTO inhibitors Drug synergies Value1 Drug Indications Mechanism References (USD) Melanoma, FTO up regulation increases melanoma growth & decreases anti-PD-1 response. FTO doi.org/10.1038/s41467-019-10669-0 Anti PD-1/ Immune $20.4 B (2018) colon cancer, inhibition sensitized melanoma to anti-PD-1 tre
Slide 15: Pillar 1 – FTO & Melanoma opportunity
PILLAR 1 – FTO & Melanoma opportunity ● One of the most dangerous cancers: 7000 deaths (USA), 1500 (Aust)1 ● Major improvements in treatment (BRAF/MEK inhibitors, immune checkpoint), but the 5-year survival rate for advanced melanoma is still as low as ~25%1 ● Major problem - treatment resistance ●
Slide 16: Pillar 1 – FTO & Clear Cell Renal cell carcinoma
PILLAR 1 – FTO & Clear Cell Renal cell carcinoma ● 10th most common cancer; often only diagnosed after metastasis1 ● New treatments. TKI, checkpoint inhibitors1 ● 5-year survival rate still very low (~12%)1 ● 90% of ccRCC are caused by mutations in the von Hippel-Lindau (VHL) tumour suppressor gene2
Slide 17: Pillar 2 - Breast cancer
PILLAR 2 - Breast cancer Phase 1/2 proof-of-concept (POC) trial in advanced metastatic breast cancer patients Preclinical data suggests Bisantrene is able to kill breast cancer cells resistant to current standard of care drugs1 Aim to demonstrate activity of Bisantrene in this patient population Pha
Slide 18: Pillar 3 - Extramedullary AML
PILLAR 3 - ExtraMedullary AML ● Why extramedullary (EM) AML? ● Recent Israel results - 4/4 responders had EM AML ● Unmet clinical need - no clinical trials and EM AML patients excluded ● EM AML patients have a worse outcome than non-EM AML patients ● PET has shown EM AML is much more common than pre
Slide 19: Rapid Progress: Announced Activities in CY 2021
Rapid Progress Announced Activities in CY 2021 ● Positive breast and ovarian cancer preclinical results ● Four preclinical programs launched in collaboration with the University of Newcastle to explore: ● Use of Bisantrene in combination with standard of care drugs for the treatment of melanoma ● Us
Slide 20: Next Steps
Next Steps 2021/2022 2021 ● Phase 2 extramedullary AML clinical trial (Australia) ● Phase 2 R/R AML combination clinical trial (Israel) ● Phase 2 clinical trial in late stage metastatic breast cancer (Australia) ● Phase 1 dose escalation trial to determine the optimal Bisantrene dosing for targeting
Slide 21: Activity Timeline
Activity TimeLine 2021 2022 2023 Preclinical melanoma All open label studies with Preclinical kidney cancer (ccRCC) continuous data readouts Preclinical EMD AML and news flows Preclinical heart safety Phase 2 Clinical Trial. Combination r/r AML Preclinical lung cancer safety Phase 1. FTO dose escala
Slide 22: Concluding comments
concluding comments STRATEGY – capitalises on FTO opportunity while protecting legacy chemotherapy credentials RISK REWARD – multi leg strategy reduces executional risk and maximises potential for outsized returns TEAM – is focused on shareholder return, via sale / license to pharma partner CLINICAL
Slide 23: Contact us
Contact us Phil Lynch, CEO/MD Dr Daniel Tillett, CSO/ED raceoncology.com phillip.lynch@raceoncology.com daniel.tillett@raceoncology.com